Navigation Links
2007 a "Record Year" for Successful Validation Studies of Simbionix Simulators
Date:12/13/2007

CLEVELAND, Ohio, December 13 /PRNewswire/ -- Ten new validation studies were published during 2007 on the Simbionix Mentor series of training simulators, bringing the total number of studies published to 65.

"This year we have seen a considerable increase in interest from US and European institutes" said Gary Zamler, Simbionix' CEO. "Some of the world's most highly respected academic medical institutions and teaching hospitals have completed studies measuring the efficacy of using Simbionix Mentor simulation products."

The studies published this year include two new studies on the GI Mentor, two on the URO/PERC platform, three on the LAP Mentor and three on the ANGIO Mentor. Some of the studies were carried out at multiple sites, something that typically increases the reliability of study results. The institutes which conducted studies include the University of Texas, Catharina Hospital of the Netherlands, the British Imperial College of London and the Graduate School of Medical Sciences in the Kyushu University of Fukuoka, the first study by a Japanese institute to date.

The study carried out by experts at Catharina Hospital's Department of Gastroenterology concluded that the GI Mentor II simulator offered a convincing, realistic representation of colonoscopy that can discriminate between different levels of colonoscopy expertise. As a result, the product was granted both construct validity and expert validity. The study carried out by Kyushu University of Fukuoka concluded that the LAP Mentor was able to differentiate between subjects with different laparoscopic experience.

One of the key value points for medical institutions to use Simbionix products is the ability to offer clinicians and medical students the required hands-on surgical experience at zero patient risk. Validation studies are critical to prove the efficacy of the simulation experience, so that institutions can rely on simulators to advance clinician training and improve patient safety. Yael Friedman Ph.D., Simbionix Chief Scientist over Medical Projects noted "We are happy to see that all of the institutes which have validated our products continue to demonstrate the effectiveness and advantage of using our Mentor products for surgical training".

Full details of the validation tests carried out can be seen on Simbionix website:

- For LAP Mentor validation tests, see http://www.simbionix.com/Media_validation_LAP.html

- For ANGIO Mentor validation tests, see http://www.simbionix.com/Media_validation_ANGIO.html

- For GI Mentor validation tests, see http://www.simbionix.com/Media_validation.html

- For URO Mentor validation tests, see http://www.simbionix.com/Media_validation_URO.html

About Simbionix USA Corporation

Simbionix is the industry leader in the development of innovative and effective medical simulation products used for clinical education and training of medical professionals. Simbionix products are designed to accelerate best-practice medical training, advance clinical performance and improve patient safety. The company is committed to continuously innovating and broadening its product offerings with a wide range of training modules, case studies and scenarios, developed in response to the growing importance of clinical training and education as a means of achieving improved patient care.
Additional company information can be found at http://www.simbionix.com

Contact:

Inbal Mazor,

VP Marketing,

mailto:inbal@simbionix.com,

+1-216-229-2040


'/>"/>
SOURCE Simbionix Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
2. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
3. EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme
4. Life on Mars pregnancy test successfully launched
5. Of mice and men: new male contraceptives successful in rodents and humans
6. Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter
7. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
8. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
9. James Webb Space Telescope marks successful completion
10. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
11. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016  Vermillion, Inc. (NASDAQ: ... gynecologic disease, today announced the formation of the Steering ... --> --> Pelvic masses can ... diagnosis and management. Once pregnancy is ruled out, pelvic ... and ovaries, advanced endometriosis, benign ovarian tumors and gastrointestinal ...
(Date:2/11/2016)... , Germany and ... -- QGEN ; Frankfurt Prime Standard: QIA) ... QIAseq Targeted RNA Panels for gene expression profiling, expanding ... sequencing (NGS). The panels enable researchers to select from ... fold changes and discover interactions between genes, cellular phenotypes ...
(Date:2/11/2016)... -- Bioethics International, a not-for-profit organization focused on the ethics and ... accessible to patients around the world, today announced that the ... of the Good Pharma Scorecard an ,Editors, ... one of BMJ Open ,s ,Most Popular Articles, which ... frequently read. Ed Sucksmith , assistant editor of ...
(Date:2/11/2016)... , Feb. 11, 2016  Spectra BioPharma Selling Solutions ... that provides biopharma companies the experience, expertise, operational ... deploy outsourced sales teams. Created in concert with ... both the strategic and tactical needs of its ... solutions through both personal and non-personal promotion. ...
Breaking Biology Technology:
(Date:2/11/2016)... Feb. 11, 2016  Vigilant Solutions announces today that its ... being used by Lee,s Summit Police ... location and arrest of a homicide suspect. ... covers around 65 square miles and is home to roughly ... has a single mobile license plate reader system and also ...
(Date:2/10/2016)... , February 10, 2016 ... According to 2016 iris recognition market report, ... recognition is more widely accepted for border ... both fingerprint and iris recognition technology in ... to avoid purchasing two individual biometrics devices. ...
(Date:2/9/2016)... (NASDAQ: AWRE ), a leading supplier of biometrics software and ... ended December 31, 2015.  --> ... million, an increase of 61% compared to $4.3 million in the ... 2015 was $2.6 million compared to $0.2 million in the fourth ... Higher revenue and operating income in the fourth quarter of ...
Breaking Biology News(10 mins):